

# GARDP: Working Globally to Address the Antimicrobial Crisis

Dr Lauren Jankelowitz

Access Lead: DNDi GARDP Southern Africa



# Antibiotics are the foundation of modern medicine

---



These drugs have helped extend life expectancy by 23 years, protecting us against harmful bacteria.

**Can you imagine a world without them?**



**Superbugs are emerging everywhere** and outsmart even the best of available antibiotics.

---

**Currently we are losing this race.** We need more innovation to keep up.



# Even the most common infections are becoming more difficult to treat

---



**Pneumonia**



**Abdominal  
infections**



**Urinary tract  
infections**

# AMR BURDEN IN AFRICA

- **Sub-Saharan Africa bears the greatest burden of deaths** from antibiotic resistance.
- In 2019, more than half of those who died were **children under the age of 5**.
- Without new antibiotics, by 2050, **over 4 million people in African countries could die** of drug-resistant infections each year





Our  
Vision

Our  
Mission



**All infections are treatable**  
for everyone, everywhere

We work with partners  
to **accelerate the**  
**development and access to**  
**treatments** for  
drug-resistant infections

# Addressing the most urgent threats to public health



## **Sepsis in children and newborns**

1 in 5 deaths due to antibiotic resistance occur in children.  
214,000 newborns die each year.



## **Serious bacterial infections in adults**

Patients undergoing common medical procedures, such as C-section, hip replacement, or chemotherapy, are at risk of acquiring bacterial infections that cannot be easily treated with commonly used antibiotics.



## **Sexually transmitted infections**

Sexually transmitted infections caused by bacteria may become untreatable with the rise of superbugs, especially gonorrhoea.





## CHILDREN'S ANTIBIOTICS



### Identified 3 potential combination treatments for neonatal sepsis

Completed one of the largest studies on babies with sepsis—3,200 newborns in 11 countries—and identified 3 promising antibiotics for use in combination (amikacin, fosfomycin, and flomoxef)



### Public health clinical trial launched

that will validate the 3 new combinations alongside currently used antibiotic combinations



### Paediatric studies on new antibiotics

Supporting paediatric studies for cefiderocol and cefepime- taniborbactam





## SERIOUS BACTERIAL INFECTIONS



### **A promising new antibiotic on track for regulatory submission**

Welcomed positive results in a phase 3 trial of cefepime- taniborbactam by Venatorx Pharmaceuticals. If approved, this will be the first antibiotic treatment to be launched in collaboration with GARDP



### **An approved antibiotic treatment**

Signed license and collaboration agreements with Shionogi and CHAI to expand access to the antibiotic cefiderocol in 135 countries – mostly low- and middle-income countries

## SEXUALLY TRANSMITTED INFECTIONS



### A new treatment for gonorrhoea in late-stage development

Conducting a global phase 3 trial in 16 sites across 5 countries to evaluate zoliflodacin, an innovative oral treatment for gonorrhoea

Completed the manufacturing of the final drug product for registration and commercialization



# GARDP sites in Africa

Sexually transmitted infections: A new treatment for gonorrhoea

- South Africa - 6 sites in clinics and communities

Serious bacterial infections: Observational study

- South Africa - 5 hospitals across 4 provinces

Neonatal sepsis: Observational study

- Tygerberg Hospital, Chris Hani Baragwanath Academic Hospital, Charlotte Maxeke Johannesburg Academic Hospital in South Africa
- Kilifi County Hospital in Kenya
- Mulago Hospital in Uganda

Neonatal sepsis: Clinical trial


- South Africa: Chris Hani Baragwanath Hospital, Charlotte Maxeke Johannesburg Academic Hospital, Tygerberg Hospital





# DNDI GARDP SOUTHERN AFRICA: A KEY PART OF GARDP'S GLOBAL NETWORK


- Co-founded by GARDP and the Drugs for Neglected Diseases initiative (DNDi)
- Began operations in 2019 as a non-profit company in South Africa
- Carried out two clinical trials on paediatric HIV and advanced HIV for DNDi in South Africa
- Conducts clinical trials and studies in GARDP's neonatal sepsis, serious bacterial infections and STI programmes at sites across South Africa.
- Works with a broad range of partners on developing treatments and access to medicines for both GARDP and DNDi
- By late-2023, we had grown to a team of 13 employees and several expert consultants



# Opportunities for GARDP in Africa

- **Encourage and promote** clinical trial networks for sepsis and sexually transmitted infections
- **Support pharmaceutical manufacturing strategies** to boost Africa's supply chain resilience
- **Engage local regulators** on AMR challenges and solutions
- **Work with partners** to speed up registration of antibiotics, access to medicines and stewardship





Financial contribution from  
Public Health Agency of Canada / Agence de la santé publique du Canada



Ministry of Health, Welfare and Sport



Co-funded by the European Union



Federal Ministry of Education and Research



Gouvernement Princier / PRINCIPAUTÉ DE MONACO



GAMRIF

Leo Model Foundation



wellcome



Schweizerische Eidgenossenschaft / Confédération suisse / Confederazione Svizzera / Confederaziun svizra / Swiss Confederation



Ministry of Foreign Affairs

# Thank you

